• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高危神经母细胞瘤肿瘤拷贝数谱的元挖掘。

Meta-mining of copy number profiles of high-risk neuroblastoma tumors.

机构信息

Center for Medical Genetics, Ghent University, Ghent, Belgium.

Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.

出版信息

Sci Data. 2018 Oct 30;5:180240. doi: 10.1038/sdata.2018.240.

DOI:10.1038/sdata.2018.240
PMID:30375995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6207068/
Abstract

Neuroblastoma, a pediatric tumor of the sympathetic nervous system, is predominantly driven by copy number aberrations, which predict survival outcome in global neuroblastoma cohorts and in low-risk cases. For high-risk patients there is still a need for better prognostic biomarkers. Via an international collaboration, we collected copy number profiles of 556 high-risk neuroblastomas generated on different array platforms. This manuscript describes the composition of the dataset, the methods used to process the data, including segmentation and aberration calling, and data validation. t-SNE analysis shows that samples cluster according to MYCN status, and shows a difference between array platforms. 97.3% of samples are characterized by the presence of segmental aberrations, in regions frequently affected in neuroblastoma. Focal aberrations affect genes known to be involved in neuroblastoma, such as ALK and LIN28B. To conclude, we compiled a unique large copy number dataset of high-risk neuroblastoma tumors, available via R2 and a Shiny web application. The availability of patient survival data allows to further investigate the prognostic value of copy number aberrations.

摘要

神经母细胞瘤是一种源于交感神经系统的小儿肿瘤,主要由拷贝数异常驱动,这些异常可预测全球神经母细胞瘤队列和低危病例的生存结果。对于高危患者,仍然需要更好的预后生物标志物。通过国际合作,我们收集了 556 例高危神经母细胞瘤的拷贝数谱,这些样本是在不同的阵列平台上生成的。本文描述了数据集的组成、用于处理数据的方法,包括分割和异常调用,以及数据验证。t-SNE 分析表明,样本根据 MYCN 状态聚类,并显示出阵列平台之间的差异。97.3%的样本具有神经母细胞瘤中常见的片段性异常。局灶性异常影响已知参与神经母细胞瘤的基因,如 ALK 和 LIN28B。总之,我们编译了一个独特的高危神经母细胞瘤肿瘤的大型拷贝数数据集,可通过 R2 和 Shiny 网络应用程序获得。患者生存数据的可用性允许进一步研究拷贝数异常的预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/2a5a4ad7d8c7/sdata2018240-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/412bea00cc7b/sdata2018240-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/690ff3a14219/sdata2018240-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/5abc3c0de91e/sdata2018240-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/6b214d3dcdce/sdata2018240-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/56f72be11fa9/sdata2018240-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/2a5a4ad7d8c7/sdata2018240-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/412bea00cc7b/sdata2018240-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/690ff3a14219/sdata2018240-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/5abc3c0de91e/sdata2018240-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/6b214d3dcdce/sdata2018240-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/56f72be11fa9/sdata2018240-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2206/6207068/2a5a4ad7d8c7/sdata2018240-f6.jpg

相似文献

1
Meta-mining of copy number profiles of high-risk neuroblastoma tumors.高危神经母细胞瘤肿瘤拷贝数谱的元挖掘。
Sci Data. 2018 Oct 30;5:180240. doi: 10.1038/sdata.2018.240.
2
Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.拷贝数异常估计:外显子测序数据与 SNP 微阵列的比较鉴定出神经母细胞瘤中 19q13.2 和 CIC 的纯合缺失。
Int J Oncol. 2016 Mar;48(3):1103-16. doi: 10.3892/ijo.2016.3349. Epub 2016 Jan 19.
3
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.基因组扩增和 6q 远端缺失:高危神经母细胞瘤患者不良生存的新标志物。
J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.
4
Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.神经母细胞瘤在诊断、治疗、复发和转移时MYCN扩增的异质性。
Genes Chromosomes Cancer. 2017 Jan;56(1):28-41. doi: 10.1002/gcc.22398. Epub 2016 Aug 18.
5
Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.对循环游离 DNA 进行浅层全基因组测序可在神经母细胞瘤患者中实现可靠的非侵入性拷贝数分析。
Clin Cancer Res. 2017 Oct 15;23(20):6305-6314. doi: 10.1158/1078-0432.CCR-17-0675. Epub 2017 Jul 14.
6
Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.神经母细胞瘤具有独特的基因组DNA图谱,可预测临床表型和区域基因表达。
Genes Chromosomes Cancer. 2007 Oct;46(10):936-49. doi: 10.1002/gcc.20477.
7
Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.神经母细胞瘤中枢神经系统转移中存在复发性的预先存在和获得性 DNA 拷贝数改变,包括局灶性 TERT 扩增。
Genes Chromosomes Cancer. 2013 Dec;52(12):1150-66. doi: 10.1002/gcc.22110. Epub 2013 Oct 10.
8
Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state.神经母细胞瘤中持续的多倍体染色体丢失导致肿瘤内染色体拷贝数的异质性。
PLoS One. 2013;8(3):e59268. doi: 10.1371/journal.pone.0059268. Epub 2013 Mar 21.
9
Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.神经元导航器 3 在神经系统肿瘤中的改变与肿瘤恶性程度和预后相关。
Genes Chromosomes Cancer. 2013 Feb;52(2):191-201. doi: 10.1002/gcc.22019. Epub 2012 Oct 25.
10
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.利用高密度单核苷酸多态性芯片进行神经母细胞瘤的全基因组分析。
PLoS One. 2007 Feb 28;2(2):e255. doi: 10.1371/journal.pone.0000255.

引用本文的文献

1
USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic Reprogramming.USP44 过表达通过表观遗传重编程驱动神经母细胞瘤中类似于 MYC 的基因表达程序。
Mol Cancer Res. 2024 Sep 4;22(9):812-825. doi: 10.1158/1541-7786.MCR-23-0454.
2
Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer.乘客基因共扩增在癌症中产生附带的治疗弱点。
Cancer Discov. 2024 Mar 1;14(3):492-507. doi: 10.1158/2159-8290.CD-23-1189.
3
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in -amplified neuroblastoma.

本文引用的文献

1
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.基因组扩增和 6q 远端缺失:高危神经母细胞瘤患者不良生存的新标志物。
J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.
2
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.《国际神经母细胞瘤反应标准修订版:美国国立癌症研究所临床试验规划会议共识声明》
J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4.
3
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
一种 MYCN 非依赖性机制介导的神经母细胞瘤中分泌组重编程和转移。
Sci Adv. 2023 Aug 25;9(34):eadg6693. doi: 10.1126/sciadv.adg6693. Epub 2023 Aug 23.
4
Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.神经母细胞瘤发生于胎儿早期发育阶段,其进化持续时间可预测结局。
Nat Genet. 2023 Apr;55(4):619-630. doi: 10.1038/s41588-023-01332-y. Epub 2023 Mar 27.
5
Precise identification of cancer cells from allelic imbalances in single cell transcriptomes.从单细胞转录组的等位基因失衡中精确识别癌细胞。
Commun Biol. 2022 Sep 7;5(1):884. doi: 10.1038/s42003-022-03808-9.
6
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.核糖核苷酸还原酶M2亚基(RRM2)增强MYCN驱动的神经母细胞瘤形成,并作为与CHK1抑制协同作用的靶点。
Sci Adv. 2022 Jul 15;8(28):eabn1382. doi: 10.1126/sciadv.abn1382. Epub 2022 Jul 13.
7
From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.从DNA拷贝数增加和肿瘤依赖性到高危神经母细胞瘤的新型治疗靶点
J Pers Med. 2021 Dec 3;11(12):1286. doi: 10.3390/jpm11121286.
8
The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome.ELOVL4 的表达受 MYCN 抑制,可定义预后良好的神经母细胞瘤患者。
Oncogene. 2021 Sep;40(38):5741-5751. doi: 10.1038/s41388-021-01959-3. Epub 2021 Jul 31.
9
resistancebank.org, an open-access repository for surveys of antimicrobial resistance in animals.resistancebank.org,一个动物抗菌药物耐药性调查的开放获取知识库。
Sci Data. 2021 Jul 22;8(1):189. doi: 10.1038/s41597-021-00978-9.
10
Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell.肿瘤与正常单细胞 mRNA 比较揭示了泛神经母细胞瘤癌细胞。
Sci Adv. 2021 Feb 5;7(6). doi: 10.1126/sciadv.abd3311. Print 2021 Feb.
神经母细胞瘤转化基因组学的进展:从改善风险分层、揭示新生物学特性到识别可操作的基因组改变。
Cancer. 2016 Jan 1;122(1):20-33. doi: 10.1002/cncr.29706. Epub 2015 Nov 5.
4
SegAnnDB: interactive Web-based genomic segmentation.SegAnnDB:交互式基于网络的基因组分割。
Bioinformatics. 2014 Jun 1;30(11):1539-46. doi: 10.1093/bioinformatics/btu072. Epub 2014 Feb 3.
5
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.拷贝数:单轨道和多轨道拷贝数分割的高效算法。
BMC Genomics. 2012 Nov 4;13:591. doi: 10.1186/1471-2164-13-591.
6
Association of age at diagnosis and genetic mutations in patients with neuroblastoma.神经母细胞瘤患者的诊断年龄与基因突变的关联。
JAMA. 2012 Mar 14;307(10):1062-71. doi: 10.1001/jama.2012.228.
7
Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.在转移性神经母细胞瘤中,基因组异常的积累和细胞周期及端粒酶基因的失调与年龄有关。
Int J Cancer. 2012 Oct 1;131(7):1591-600. doi: 10.1002/ijc.27432. Epub 2012 Feb 18.
8
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.鉴定高危 MYCN 单拷贝 11q 缺失神经母细胞瘤中新型 1q42.2-1qter 重复缺失。
Int J Cancer. 2012 Jun 1;130(11):2599-606. doi: 10.1002/ijc.26317. Epub 2011 Aug 29.
9
Outcomes for children and adolescents with cancer: challenges for the twenty-first century.儿童和青少年癌症患者的预后:二十一世纪的挑战。
J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421. Epub 2010 Apr 19.
10
The pitfalls of platform comparison: DNA copy number array technologies assessed.平台比较的陷阱:评估 DNA 拷贝数阵列技术。
BMC Genomics. 2009 Dec 8;10:588. doi: 10.1186/1471-2164-10-588.